Results 31 to 40 of about 5,527 (127)

Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review

International Journal of Urology, Volume 32, Issue 5, Page 475-487, May 2025.
ABSTRACT The incidence of prostate cancer (PC) has recently increased in Japan. Androgen deprivation therapy (ADT) has been a key treatment in patients with castration‐sensitive PC (CSPC); however, resistance typically emerges through multiple mechanisms, leading to metastatic castration‐resistant PC (mCRPC).
Kazuhiro Suzuki, Hideyasu Matsuyama, Nobuaki Matsubara, Hirotaka Kazama, Fumiko Ueno, Hirotsugu Uemura   +5 more
wiley   +1 more source

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis [PDF]

, 2015
BackgroundESPRIT is an ongoing, 10-year, observational registry, evaluating long-term safety and effectiveness of adalimumab treatment in routine clinical practice for patients with moderate to severe, chronic plaque psoriasis.ObjectivesInitial 5-year ...
Bereswill, Mareike, Menter, Alan, Papp, Kim A., Rubant, Simone, Teixeira, Henrique D., Thaçi, Diamant, Williams, David A., Wu, Jashin J.   +7 more
core   +1 more source

What Affects the Quality of Pharmacovigilance? Insights From Qualitative Comparative Analysis

Pharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.
ABSTRACT Pharmacovigilance plays a significant role in guaranteeing the safety of medications for patients. Over the last three decades, China has significantly advanced its pharmacovigilance practices, yet the factors that drive the quality of pharmacovigilance remain unclear.
Yadong Wang, Yue Chen, Xingjuan Xu, Ting Ying, Runan Xia, Yuanyuan Zhang, Xuefeng Xie   +6 more
wiley   +1 more source

Information and communication technology solutions for outdoor navigation in dementia [PDF]

, 2016
INTRODUCTION: Information and communication technology (ICT) is potentially mature enough to empower outdoor and social activities in dementia. However, actual ICT-based devices have limited functionality and impact, mainly limited to safety. What is an
Aloulou, Alwin, American Psychiatric Association A, Arribas-Ayllon, Aspden, Austin, Baglio, Boger, Borson, Bosboom, Bradley, Brittain, Buschert, Chapman, Cipriani, Claudio Babiloni, Cosentino, De Raedt, Dodge, Drago, Free, Gillespie, Hattink, Heise, Henderson, Hoey, Honig, Jeffrey Kaye, Jesse Hoey, Kasper, Khosravi, Kirste, Koldrack, Krüger, Lancioni, Lancioni, Laske, Levinson, Lively, Milne, Mitchell, Niemeijer, Oliver K. Burmeister, Olsson, Passini, Patterson, Petersen, Rizzolatti, Robert, Russel, Schikhof, Serna, Shani, Smit, Solanas, Stefan Teipel, Strohminger, Thomas Kirste, Tung, Veldkamp   +59 more
core   +1 more source

Understanding the Mechanism of Cardiotoxicity Induced by Nanomaterials: A Comprehensive Review

Small Science, Volume 5, Issue 5, May 2025.
This review provides a bibliometric analysis for understanding the study of nanotoxicity on cardiovascular health. It begins by outlining the pathways through which nanomaterials enter the cardiovascular system, followed by a summary of the mechanisms underlying nanomaterial‐induced cardiotoxicity.
Zaiyong Zheng, Shuang Zhu, Xiaobo Wang, Haoran Wu, Min Fu, Houxiang Hu, Zhanjun Gu, Chunxiang Zhang   +7 more
wiley   +1 more source

Applications of Artificial Intelligence in Drug Repurposing

Advanced Science, Volume 12, Issue 14, April 10, 2025.
Artificial intelligence algorithms are transforming drug repurposing by revealing new therapeutic targets and mechanisms. This review highlights the integration of AI frameworks, multimodal datasets, and advanced optimization methods, accelerating the discovery of new indications for existing drugs.
Zhaoman Wan, Xinran Sun, Yi Li, Tianyao Chu, Xueyu Hao, Yang Cao, Peng Zhang   +6 more
wiley   +1 more source

AI‐Driven Applications in Clinical Pharmacology and Translational Science: Insights From the ASCPT 2024 AI Preconference

Clinical and Translational Science, Volume 18, Issue 4, April 2025.
ABSTRACT Artificial intelligence (AI) is driving innovation in clinical pharmacology and translational science with tools to advance drug development, clinical trials, and patient care. This review summarizes the key takeaways from the AI preconference at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2024 Annual Meeting in ...
Mohamed H. Shahin, Prashant Desai, Nadia Terranova, Yuanfang Guan, Tomáš Helikar, Sebastian Lobentanzer, Qi Liu, James Lu, Subha Madhavan, Gary Mo, Flora T. Musuamba, Jagdeep T. Podichetty, Jie Shen, Lei Xie, Mathew Wiens, Cynthia J. Musante   +15 more
wiley   +1 more source

What is the addiction risk associated with tramadol? [PDF]

, 2005
Tramadol (Ultram, generic and with acetaminophen in Ultracet) carries a risk of substance abuse (strength of recommendation [SOR]: B, based on case report surveillance programs).
Mackler, Leslie, McDiarmid, Todd
core  

Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety

Cancer, Volume 131, Issue 1, 1 January 2025.
Abstract The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib was approved by the US Food and Drug Administration in 2014 for treatment of patients with polycythemia vera (PV) who have an inadequate response to or intolerance of hydroxyurea (HU).
Lucia Masarova, John Mascarenhas, Raajit Rampal, Wilson Hu, Robert A. Livingston, Naveen Pemmaraju   +5 more
wiley   +1 more source

Post‐Market Evidence for Cancer Medicines in Regulatory and Clinical Decision‐Making: A Scoping Review

Pharmacoepidemiology and Drug Safety, Volume 34, Issue 1, January 2025.
ABSTRACT Background Cancer medicines usually have uncertain efficacy and safety profiles when they are first approved by medicines regulators because this evidence usually emerges post‐market. Little is known about the extent to which post‐market evidence is evaluated and integrated into evidence review processes in regulatory and clinical contexts ...
Eliza J. McEwin, Ashleigh Hooimeyer, Barbara J. Mintzes   +2 more
wiley   +1 more source